

References

1. Substance Use and Mental Health Services Administration. *Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health*. <https://www.samhsa.gov/data/>
2. National Institute of Drug Abuse. National Drug Overdose Deaths by Specific Category—Number Among All Ages, 1999–2018. Accessed 11/15/20, <https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates>
3. CDC. Overdose Deaths and the Involvement of Illicit Drugs: Urgent Need for Overdose Prevention Interventions. Accessed 11/15/20, <https://www.cdc.gov/drugoverdose/pubs/featured-topics/VS-overdose-deaths-illicit-drugs.html>
4. Substance Use and Mental Health Services Administration. *The Opioid Crisis and the Black/African American Population: An Urgent Issue*. 2020. Accessed 11/18/20. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-05-02-001_508%20Final.pdf
5. Substance Use and Mental Health Services Administration. 2019 NSDUH Detailed Tables. <https://www.samhsa.gov/data/report/2019-nsduh-detailed-tables>
6. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. *Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017*. Vol. 67. 2018:1419–1427. https://www.cdc.gov/mmwr/volumes/67/wr/mm675152e1.htm?s_cid=mm675152e1_w#T1_d own
7. Lippold K, Jones C, Olsen E, Giroir B. *Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid-Involved Overdose Deaths Among Adults Aged ≥18 Years in Metropolitan Areas — United States, 2015–2017*. Vol. 68. 2019:967–973. <https://www.cdc.gov/mmwr/volumes/68/wr/mm6843a3.htm>
8. Wilson N, Kariisa M, Seth P, Smith H, Davis N. Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018. CDC: Morbidity and Mortality Weekly Report; 2020. p. 290–297.
9. Centers for Disease Control and Prevention. *2019 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report*. 2019. <https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf>
10. Netherland J, Hansen H. White opioids: Pharmaceutical race and the war on drugs that wasn't. *Biosocieties*. Jun 2017;12(2):217–238. doi:10.1057/biosoc.2015.46
11. Sacco L. *Drug Enforcement in the United States: History, Policy, and Trends*. 2014. <https://digital.library.unt.edu/ark:/67531/metadc463078/>
12. Wright, Hamilton. Report of the International Opium Commission, Shanghai, China, February 1 to February 26, 1909. North-China Daily News & Herald. <https://archive.org/details/cu31924032583225>
13. Williams E. Negro Cocaine 'Fiends' Are a New Southern Menace. *New York Times*.
14. Nixon R. Remarks About an Intensified Program for Drug Abuse Prevention and Control. The American Presidency Project. <http://www.presidency.ucsb.edu/ws/index.pid?pid=3047>

15. DEA. DEA History. <https://www.dea.gov/history>
16. Netherland J, Hansen HB. The War on Drugs That Wasn't: Wasted Whiteness, "Dirty Doctors," and Race in Media Coverage of Prescription Opioid Misuse. *Culture, medicine and psychiatry*. 2016;40(4):664-686. doi:10.1007/s11013-016-9496-5
17. Bureau of Justice Statistics. Drug And Crime Facts. <https://www.bjs.gov/content/dcf/tables/arrtot.cfm>
18. Lassiter MD. Impossible Criminals: The Suburban Imperatives of America's War on Drugs. *Journal of American History*. 2015;102(1):126-140. doi:10.1093/jahist/jav243
19. FBI. 2018 Crime in the United States: Arrests by Race and Ethnicity. <https://ucr.fbi.gov/crime-in-the-u.s/2018/crime-in-the-u.s.-2018/tables/table-43>
20. Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. *The journal of behavioral health services & research*. 2013;40(3):367-377. doi:10.1007/s11414-013-9341-3
21. Stahler GJ, Mennis J. Treatment outcome disparities for opioid users: Are there racial and ethnic differences in treatment completion across large US metropolitan areas? *Drug Alcohol Depend*. Sep 1 2018;190:170-178. doi:10.1016/j.drugalcdep.2018.06.006
22. Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race/Ethnicity and Payment. *JAMA Psychiatry*. 2019;76(9):979-981. doi:10.1001/jamapsychiatry.2019.0876
23. Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder--and its treatment. *Jama*. Apr 9 2014;311(14):1393-4. doi:10.1001/jama.2014.2147
24. Hatcher AE, Mendoza S, Hansen H. At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care". *Subst Use Misuse*. Jan 28 2018;53(2):301-310. doi:10.1080/10826084.2017.1385633
25. Greenwald G. Drug Decriminalization in Portugal: Lessons for Creating Fair and Successful Drug Policies. Washington D.C.: Cato Institute; 2009.
26. Service of Intervention in Addictive Behaviors and Dependencies. Statistical Bulletin Synopsis 2018 Illicit Substances. http://www.sicad.pt/EN/Paginas/detalhe.aspx?itemId=56&lista=SICAD_DESTAQUES&bkUrl=/BK
27. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. *Am J Addict*. 2004;13 Suppl 1:S17-28. doi:10.1080/10550490490440780